← All trials
NCT04706507
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 29, 2021
- Primary completion
- May 31, 2026
- Completion date
- Aug 31, 2027
- First posted
- Jan 12, 2021
- Last posted
- Nov 12, 2021
- Enrollment
- 485
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of WashingtonLead sponsor
- University of WashingtonReponsible party - principal investigator
- University of WashingtonOverall official - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.